Recombinant Human 4-1BB Ligand/TNFSF9 protein (hFc Tag)

ED50

6-24 ng/mL

Species

Human

Purity

>95 %, SDS-PAGE

GeneID

8744

Accession

P41273

Cat No : Eg0079

Print datasheet

Synonyms

4-1BB Ligand, 4-1BBL, CD137L, TNFSF9



Technical Specifications

Purity >95 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Immobilized Human 4-1BB (Myc tag, His tag) at 0.5 μg/mL (100 μL/well) can bind Human 4-1BB Ligand (hFc tag) with a linear range of 6-24 ng/mL.
Source HEK293-derived Human 4-1BB Ligand protein Arg71-Glu254 (Accession# P41273) with a human IgG1 Fc tag at the N-terminus.
Predicted Molecular Mass 45.4 kDa
SDS-PAGE 45-50 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

TNFSF9 (Tumor necrosis factor ligand superfamily member 9) is also known as 4-1BBL (4-1BB ligand) or CD137L. TNFSF9 is a type 2 transmembrane glycoprotein receptor that is found on APCs (antigen presenting cells). TNFSF9 is expressed on activated T Lymphocytes. The TNFSF9/4-1BB complex with the help of T-cell receptor signals can trigger the increase in CD28− T cells and inhibit tumor growth. The interaction between 4-1BB and TNFSF9 provides costimulatory signals to T cells, which can be used to cancer immunotherapy.

References:

1.Jacob Bukczynski. et al. (2003). Eur J Immunol. 33(2): 446-54. 2.Adam T C Cheuk. et al. (2004). Cancer Gene Ther. 11(3): 215-26. 3.Chao Wang. et al. (2009). Immunol Rev. 229(1): 192-215. 4.Dass S Vinay. et al. (2012). Mol Cancer Ther. 11(5): 1062-1070. 5.Cariad Chester. et al. (2018). Blood. 131(1): 49-57.